A loading dose of teicoplanin in critically ill patients: effectiveness of dosing determined by data analysis software.
Phase 4
- Conditions
- Gram-positive infections
- Registration Number
- JPRN-UMIN000002149
- Lead Sponsor
- Emergency and Critical Care Medicine, the University of Tokushima graduate school
- Brief Summary
21st annual congress, European society of intensive care medicine
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
hemodialysis therapy, infective endocarditis and purulent osteomyelitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method trough concentration of teicoplanin at 24, 48, 72hrs after first administration.
- Secondary Outcome Measures
Name Time Method The duration of ICU stay and mortality rate
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie teicoplanin's efficacy against Gram-positive infections in ICU patients?
How does software-guided teicoplanin loading compare to standard-of-care dosing for critically ill Gram-positive infection cases?
Are specific biomarkers identified in JPRN-UMIN000002149 to predict teicoplanin response in septic shock patients?
What adverse events are associated with high-dose teicoplanin loading in ICU settings and how are they managed?
How does teicoplanin loading strategy in JPRN-UMIN000002149 align with other glycopeptide antibiotics like vancomycin in treating MRSA infections?